Loading...
Loading...
Browse all stories on DeepNewz
VisitFDA Approves Illumina's TruSight Oncology Comprehensive for Bayer and Lilly Therapies
Aug 27, 2024, 02:01 PM
The U.S. Food and Drug Administration (FDA) has approved Illumina's TruSight Oncology Comprehensive assay, a cancer biomarker test designed to rapidly match patients to targeted therapies. This test includes two companion diagnostics and is specifically approved as a companion diagnostic (CDx) for kinase inhibitors from pharmaceutical companies Bayer and Lilly. The assay identifies patients with NTRK gene fusions who may benefit from Bayer's Vitrakvi (larotrectinib) and those with RET fusion-positive cancers who may benefit from Lilly's Retevmo (selpercatinib).
View original story
Markets
Yes • 50%
No • 50%
Prescription data from pharmaceutical reports or healthcare databases
No • 50%
Yes • 50%
Hospital adoption reports or healthcare industry surveys
No • 50%
Yes • 50%
FDA approval announcements
Both equally • 25%
Neither • 25%
NTRK gene fusion cancers • 25%
RET fusion-positive cancers • 25%
Medical journals and healthcare reports
Roche • 25%
Pfizer • 25%
Other • 25%
Merck • 25%
Official partnership announcements or press releases
Other • 25%
Illumina • 25%
Bayer • 25%
Lilly • 25%
Stock market data from financial reports